Infinity Pharmaceuticals Inc. (INFI)

1.58
0.01 0.63
NASDAQ : Health Technology
Prev Close 1.59
Open 1.62
Day Low/High 1.57 / 1.62
52 Wk Low/High 1.00 / 2.92
Volume 28.02K
Avg Volume 110.20K
Exchange NASDAQ
Shares Outstanding 56.93M
Market Cap 91.08M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Infinity Announces The Date Of Its Third Quarter 2013 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Third Quarter 2013 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, November 7, 2013, at 4:30 p.

Bulls Bet Infinity Pharma Will Rebound

Bulls Bet Infinity Pharma Will Rebound

Infinity Pharmaceuticals has tumbled since the spring, but Tuesday the bulls were back in the name.

RSI Alert For Infinity Pharmaceuticals (INFI)

RSI Alert For Infinity Pharmaceuticals (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Reports Topline Data From Phase 2 Study Of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, In Patients With Non-Small Cell Lung Cancer

Infinity Reports Topline Data From Phase 2 Study Of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, In Patients With Non-Small Cell Lung Cancer

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock protein 90 (Hsp90) inhibitor, in patients with ...

Julian Adams, Ph.D., Of Infinity Pharmaceuticals Named Corporate Chair For The Leukemia & Lymphoma Society’s Light The Night Walk

Julian Adams, Ph.D., Of Infinity Pharmaceuticals Named Corporate Chair For The Leukemia & Lymphoma Society’s Light The Night Walk

The Massachusetts chapter of The Leukemia & Lymphoma Society (LLS) named Julian Adams, Ph.

Infinity Expands Executive Leadership Team, Appointing David A. Roth As Senior Vice President, Clinical Development And Medical Affairs

Infinity Expands Executive Leadership Team, Appointing David A. Roth As Senior Vice President, Clinical Development And Medical Affairs

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the appointment of David A.

Infinity Supports Blood Cancer Awareness Month With Launch Of Sparks Of Inspiration, A Campaign To Honor People Affected By Blood Cancer

Infinity Supports Blood Cancer Awareness Month With Launch Of Sparks Of Inspiration, A Campaign To Honor People Affected By Blood Cancer

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is observing National Blood Cancer Awareness Month, joining patients, healthcare providers and patient organizations in raising public awareness of blood cancers and ...

Infinity To Participate In Three Conferences In September

Infinity To Participate In Three Conferences In September

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in three conferences during September.

Infinity Reports Second Quarter 2013 Financial Results And Provides Company Update

Infinity Reports Second Quarter 2013 Financial Results And Provides Company Update

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported its second quarter 2013 financial results and provided an update on its clinical pipeline.

5 Stocks Poised to Pop on Bullish Earnings

5 Stocks Poised to Pop on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings.

Infinity Announces The Date Of Its Second Quarter 2013 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Second Quarter 2013 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, August 8, 2013, at 8:30 a.

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Infinity Pharmaceuticals was a leading decliner within the drugs industry, falling $0.51 (-3.1%) to $15.95 on light volume

Infinity To Present At The 2013 JMP Securities Healthcare Conference

Infinity To Present At The 2013 JMP Securities Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 2013 JMP Securities Healthcare Conference on July 9, 2013, at 1:00 p.

Best And Worst Performing Biotech Stocks In the Second Quarter

Best And Worst Performing Biotech Stocks In the Second Quarter

Clovis Oncology and Stemline Therapeutics were among the best-performing biotech stocks in the June quarter.

Infinity Reports Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 Across A Broad Range Of Blood Cancers At The 12th International Conference On Malignant Lymphoma

Infinity Reports Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 Across A Broad Range Of Blood Cancers At The 12th International Conference On Malignant Lymphoma

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced...

Interesting INFI Put And Call For June 28th

Interesting INFI Put And Call For June 28th

Investors in Infinity Pharmaceuticals Inc saw new options become available today, for the June 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new June 28th contracts and identified one put and one call contract of particular interest.

Winners And Losers in CLL at ASCO '13

Winners And Losers in CLL at ASCO '13

Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.

Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Infinity Pharmaceuticals was a leading decliner within the drugs industry, falling $0.58 (-3.0%) to $18.53 on average volume

INFI June 14th Options Begin Trading

INFI June 14th Options Begin Trading

Investors in Infinity Pharmaceuticals Inc saw new options begin trading today, for the June 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new June 14th contracts and identified one put and one call contract of particular interest.

Infinity Stock Falls On Unusually High Volume (INFI)

Infinity Stock Falls On Unusually High Volume (INFI)

Infinity Pharmaceuticals (Nasdaq:INFI) is trading at unusually high volume Wednesday with three million shares changing hands. It is currently at two times its average daily volume and trading down $1.43 (-7.1%).

RSI Alert For Infinity Pharmaceuticals (INFI)

RSI Alert For Infinity Pharmaceuticals (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Stock Gaps Down On Today's Open (INFI)

Infinity Stock Gaps Down On Today's Open (INFI)

Shares of Infinity Pharmaceuticals (Nasdaq:INFI) were gapping down Monday morning with an open price 16.2% lower than Friday's closing price. The stock closed at $26.95 yesterday and opened today's trading at $22.59.

ASCO '13 Live Blog: Prepping for Monday Trading

ASCO '13 Live Blog: Prepping for Monday Trading

Charting the drug and biotech stocks which came out ahead at this weekend's ASCO annual meeting, and those that fell behind.

INFI June 7th Options Begin Trading

INFI June 7th Options Begin Trading

Investors in Infinity Pharmaceuticals Inc saw new options begin trading today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new June 7th contracts and identified one put and one call contract of particular interest.

Quick Take: The Next Big Thing in Biotech

Quick Take: The Next Big Thing in Biotech

TheStreet's senior columnist Adam Feuerstein and Gregg Greenberg discuss winners and losers from research abstracts ahead of the ASCO cancer conference.

Biotech's Next Big Thing -- ASCO II

Biotech's Next Big Thing -- ASCO II

TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.

Infinity Pharmaceuticals (INFI) Shares Cross Below 200 DMA

Infinity Pharmaceuticals (INFI) Shares Cross Below 200 DMA

In trading on Thursday, shares of Infinity Pharmaceuticals Inc crossed below their 200 day moving average of $30.69, changing hands as low as $25.95 per share. Infinity Pharmaceuticals Inc shares are currently trading off about 16.4% on the day.

ASCO '13 Preview: Gilead's Big Cancer Debut

ASCO '13 Preview: Gilead's Big Cancer Debut

More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.

10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

TheStreet Quant Rating: D (Sell)